Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K for the month of February 2023. The report was signed by Chairman Geoffrey P. Kempler on February 2, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate notifications rather than financial performance data.
Material Changes
The primary material event disclosed is the cessation of securities trading under the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities into the company's existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the reason for its cessation.
- Confirm the impact of the cessation on the company's existing Registration Statements (S-8 and F-3).
- Review subsequent filings for updated financial data, as this report contains no financial metrics.